Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Amgen.

Medical Crossfire®: BiTE Technology Around the Globe: Improving Outcomes for Patients With Acute Lymphoblastic Leukemia

Release Date: September 28, 2018
Expiration Date: September 28, 2019
Media: Internet - based

Activity Overview

Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy that continues to pose challenges for patients and oncologists alike. The foundation for the use of targeted therapies in the treatment of this disorder continues to grow, with new options such as bispecific T-cell engagers, CAR-T therapy, and antibody-drug conjugates shaping the treatment paradigm. While these treatment options have the potential to improve outcomes for your patients, they also present new challenges with respect to assessment of the safety and efficacy of new therapies and development of optimal strategies to incorporate them, when appropriate. Through a combination of didactic presentation and lively discussion, our panel of experts in the management of patients with ALL will cover a wide range of topics to help you meet these challenges. You will gain expert perspectives on key data from clinical studies in ALL, the implications of minimal residual disease (MRD) assessment, and the therapeutic implications of recent and ongoing studies.

Benefits of Completing Activity

By participating in this exciting program, you will learn about:

  • Solidify your familiarity with the latest data on bispecific T-cell engagers and other new therapies used in the treatment of ALL
  • Absorb the perspectives of leading clinical experts on methods to improve the management of patients with ALL
  • Gain insights into the management of challenging real-world clinical scenarios for patients with ALL

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Amgen.


Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, and fellows who treat patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies are also invited to participate.

Learning Objectives

Upon completion of this activity, you should be better prepared to:

  • Describe the biology of ALL in terms of biomarkers, testing strategies, and methods to stratify risk for patients with this hematologic malignancy
  • Differentiate the role of bispecific T-cell engagers and MRD status in treatment decisions for patients with ALL following induction therapy
  • Incorporate key findings from recent clinical trials concerning the use of bispecific T-cell engager treatment strategies for patients with ALL in the frontline and relapsed/refractory settings into practice
  • Discuss the recent evidence and clinical trials involving bispecific T-cell engagers in other hematologic malignancies.

Faculty, Staff, and Planners' Disclosures


Elias Jabbour, MD
Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: Grant/Research Support: Amgen, Pfizer, Takeda, Adaptive Biotechnologies, Novartis, Spectrum, AbbVie, Bristol-Myers Squibb


Marcos de Lima, MD
Professor of Medicine
Case Western Reserve University School of Medicine
Director, Hematologic Malignancies and Stem Cell Transplant Program
University Hospitals Seidman Cancer Center
Cleveland, OH

Disclosure: Grant/Research Support: Celgene; Consultant: Celgene, Pfizer

Jae H. Park, MD
Assistant Attending Physician
Department of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Consultant: Amgen, Novartis, Adaptive Biotechnologies

José María Ribera, MD
Associate Professor in Medicine
Autonomous University of Barcelona
Head, Clinical Hematology
Catalan Institute of Oncology at HUGTP in Badalona
Director, Stem Cell Transplantation Unit, HUGTP
Barcelona, Spain

Disclosure: Grant/Research Support: Amgen, Pfizer, Shire; Consultant: Amgen, Pfizer, Shireies

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By